Selective main portal vein clamping to minimize the risk of recurrence after curative liver resection for hepatocellular carcinoma.
OBJECTIVE
Our aim was to compare the postoperative outcomes of partial hepatectomy using Pringle maneuver and selective main portal vein clamping.


METHODS
From January 2004 to December 2006, 169 consecutive patients received liver resection by the same surgical team. The surgical techniques were the same for all patients except for the hepatic vascular inflow occlusion techniques during liver parenchymal transection. Patients either received clamping of the portal triad (PTC group, n=118) or selective main portal vein clamping (PVC group, n=51).


RESULTS
Operative time to carry out PVC was significantly longer than PTC (110.6±21.8 vs. 129.6±29.8min), however intraoperative blood loss was the same. There was no significant difference in operative mortality or morbidity rates, although the liver function recovered quicker in the PVC group. Significantly more patients in the PTC group developed HCC recurrence at postoperative one year than the PVC group (60.2% vs. 33.3%). There was no significant difference in overall survival between the 2 groups. Univariate analysis showed that clamping method, tumor size and BCLC grade were risk factors for disease-free survival (DFS) at one year, and multivariate analyses demonstrated clamping method and AFP level as independent risk factors for DFS.


CONCLUSIONS
Patients subjected to selective portal vein clamping did better than those to Pringle maneuver in the postoperative outcomes. The underlying mechanism may be I/R injury of the liver remnant which might also contribute to an increase in tumor recurrence after liver resection.
The Third Department of Hepatic Surgery, Second Military Medical University, Shanghai, China.
Yuan
Y
Yang
Si-Yuan
SY
Fu
Wan Yee
WY
Lau
Eric Ch
ECh
Lai
Ai-Jun
AJ
Li
Ze-Ya
ZY
Pan
Wei-Ping
WP
Zhou
Feng
F
Shen
Meng-Chao
MC
Wu
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016063:Blood Loss, Surgical; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D003250:Constriction; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008099:Liver / Q000502:physiology; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy*; D011169:Portal Vein; D016016:Proportional Hazards Models; D020127:Recovery of Function; D013125:Spinal Neoplasms / Q000556:secondary; D013997:Time Factors
D000970:Antineoplastic Agents